Cardiovascular

FDA approves Brilinta for ACSs

The U.S. Food and Drug Administration (FDA) has approved Brilinta (ticarelor) for reducing cardiovascular death and heart attack in patients with acute coronary syndromes (ACSs). Read more..


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares